Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A1 | P68400 | 10/20 | 0.39 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.35 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.35 |
| ▸ | CNR1 | P21554 | 2/20 | 0.35 |
| ▸ | CNR2 | P34972 | 2/20 | 0.35 |
| ▸ | HAO1 | Q9UJM8 | 4/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.33 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10135115 | 0.89 | CSNK2A1 (0.42) | CSNK2A1CSNK2A2CSNK2BSMN1; SMN2 | |
| SCHEMBL2689569 | 0.84 | CSNK2A1 (0.44) | CSNK2A1CSNK2A2CSNK2BSMN1; SMN2 | |
| SCHEMBL10135116 | 0.83 | CYP19A1 (0.43) | CSNK2A1CSNK2A2CSNK2BCNR1CNR2 | |
| SCHEMBL13688071 | 0.83 | CSNK2A1 (0.42) | CSNK2A1CSNK2A2CSNK2BTRPA1MAP4K4 | |
| SCHEMBL10135113 | 0.81 | CSNK2A1 (0.38) | CSNK2A1CSNK2A2CSNK2BMAP4K4 | |
| SCHEMBL10135114 | 0.80 | RAB9A (0.47) | CSNK2A1CSNK2A2CSNK2BSMN1; SMN2 | |
| SCHEMBL10135095 | 0.75 | CSNK2A1 (0.43) | CSNK2A1CSNK2A2CSNK2BCNR1MAP4K4 | |
| SCHEMBL10135098 | 0.72 | CSNK2A1 (0.45) | CSNK2A1CSNK2A2CSNK2BCNR1 | |
| SCHEMBL11932491 | 0.72 | CSNK2A1 (0.45) | CSNK2A1CSNK2BMAP4K4GAA | |
| SCHEMBL1451465 | 0.72 | CSNK2A1 (0.45) | CSNK2A1CSNK2BMAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120208792-A1 | PROTEIN KINASE MODULATORS | CYLENE PHARMACEUTICALS, INC. (US) | 2012-08-16 | — | — | US | disclosed |
| US-20120208792-A1 | PROTEIN KINASE MODULATORS | CYLENE PHARMACEUTICALS, INC. (US) | 2012-08-16 | — | — | US | disclosed |
| US-8168651-B2 | Protein kinase modulators | CYLENE PHARMACEUTICALS, INC. (US) | 2012-05-01 | — | — | US | disclosed |
| US-8168651-B2 | Protein kinase modulators | CYLENE PHARMACEUTICALS, INC. (US) | 2012-05-01 | — | — | US | disclosed |
| US-20090239859-A1 | PROTEIN KINASE MODULATORS | SENHWA BIOSCIENCES, INC. (TW) | 2009-09-24 | — | — | US | disclosed |
| US-20090239859-A1 | PROTEIN KINASE MODULATORS | SENHWA BIOSCIENCES, INC. (TW) | 2009-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120208792-A1 | PROTEIN KINASE MODULATORS | PIM1, PIM2, PIM3 | CSNK2A1 680/4885CSNK2A2 810/4885CSNK2B 772/4885 |
| US-20090239859-A1 | PROTEIN KINASE MODULATORS | PIM1, PIM2, PIM3 | CSNK2A1 680/4885CSNK2A2 810/4885CSNK2B 772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.